Browse
We’re here to help

Find guidance on Author Services

Search
Browse
We’re here to help

Find guidance on Author Services

Home
All Journals
Leukemia & Lymphoma
List of Issues
Volume 61, Issue 7
Prognosis of MECOM (EVI1)-rearranged MDS ....

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Leukemia & Lymphoma Volume 61, 2020 - Issue 7

Submit an article Journal homepage

761

Views

CrossRef citations to date

Altmetric

Letters to the Editor

Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

Isolde SummererMLL Munich Leukemia Laboratory, Munich, Germany

Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany

Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany

Wolfgang KernMLL Munich Leukemia Laboratory, Munich, Germany

Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany

Anna StengelMLL Munich Leukemia Laboratory, Munich, GermanyCorrespondence[email protected]

Pages 1756-1759 | Received 05 Feb 2020, Accepted 26 Feb 2020, Published online: 19 Mar 2020

Cite this article
https://doi.org/10.1080/10428194.2020.1737689
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions

Supplemental material

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Information for

Authors
R&D professionals
Editors
Librarians
Societies

Open access

Overview
Open journals
Open Select
Dove Medical Press
F1000Research

Opportunities

Reprints and e-prints
Advertising solutions
Accelerated publication
Corporate access solutions

Help and information

Help and contact
Newsroom
All journals
Books

Keep up to date

Sign me up

Taylor and Francis Group Facebook page

Taylor and Francis Group X Twitter page

Taylor and Francis Group Linkedin page

Taylor and Francis Group Youtube page

Taylor and Francis Group Weibo page

Registered in England & Wales No. 3099067
5 Howick Place | London | SW1P 1WG

Your download is now in progress and you may close this window

Login or register to access this feature

Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

GLAL-2020-0089-File012.pdf

GLAL-2020-0089-File011.pdf

GLAL-2020-0089-File010.pdf

GLAL-2020-0089-File009.pdf

GLAL-2020-0089-File008.pdf

GLAL-2020-0089-File007.pdf

GLAL-2020-0089-File006.pdf

GLAL-2020-0089-File005.jpg

GLAL-2020-0089-File004.jpg

GLAL-2020-0089-File003.docx